Thyroid Cancer Cell Models for Research

Thyroid cancer is the most common endocrine malignancy. According to the World Health Organization (WHO) GLOBOCAN 2022, there were approximately 821,000 new cases and 47,000 deaths worldwide annually. Incidence has risen steadily over the past three decades, partly due to increased detection of small nodules, but mortality has remained relatively stable. The American Cancer Society (via NCI SEER) reports a 5-year survival rate of nearly 99% for localized disease, dropping to 78% for regional spread and 55% for distant metastasis. Risk factors include ionizing radiation exposure, family history, and certain genetic syndromes (e.g., familial adenomatous polyposis, Cowden syndrome). The disease is notable for a strong female predominance (3:1) and a peak incidence in the 40-60 age group.

Thyroid cancer is an ideal model for studying oncogene addiction and targeted therapy resistance due to its well-characterized molecular subtypes: papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic (ATC). PTC and ATC are driven by MAPK pathway alterations (BRAF, RAS, RET), while MTC is driven by RET mutations. Public datasets such as The Cancer Genome Atlas (TCGA) and the Catalogue of Somatic Mutations in Cancer (COSMIC) provide extensive genomic, transcriptomic, and epigenetic data. Open research questions include the mechanisms of dedifferentiation to ATC, the role of the tumor microenvironment, and the development of effective therapies for radioiodine-refractory disease. Gene-edited cell models are essential for functional validation of these drivers and for testing novel therapeutic combinations.

Thyroid cancer pathogenesis is dominated by the MAPK and PI3K/AKT signaling pathways. The following are the major carcinogenic pathways:

• • MAPK/ERK pathway: Activation via BRAF V600E mutations, RAS mutations, or RET fusions leads to constitutive signaling, promoting cell proliferation and survival.
• • PI3K/AKT/mTOR pathway: Mutations in PIK3CA, PTEN loss, or AKT activation contribute to follicular and anaplastic thyroid cancer.
• • Wnt/β-catenin pathway: Aberrant activation, often via CTNNB1 mutations, is common in poorly differentiated and anaplastic thyroid cancers.
• • DNA damage response: TP53 mutations impair cell cycle checkpoints and apoptosis, enabling genomic instability and progression to ATC.

The following table summarizes high-frequency genetic alterations in thyroid cancer, based on TCGA and COSMIC data:

The deregulated signaling networks in thyroid cancer include:

• • MAPK pathway: Key nodes are RAS, RAF (BRAF), MEK, and ERK. BRAF V600E is the most common alteration, leading to sustained ERK phosphorylation.
• • PI3K/AKT/mTOR pathway: PTEN loss, PIK3CA mutations, and AKT activation are common in aggressive subtypes.
• • Wnt/β-catenin pathway: CTNNB1 mutations lead to nuclear β-catenin accumulation and transcription of target genes (e.g., MYC, CCND1).
• • NF-κB pathway: Often activated in ATC, promoting inflammation and survival.
• • Cell cycle and apoptosis: TP53 mutations disrupt G1/S checkpoint and apoptosis, while CDK4/6 overexpression is seen in some ATCs.

Common thyroid cancer cell lines and organoid models are listed below:

Organoid models derived from patient tumors retain the heterogeneity and 3D architecture of the original tumor, making them valuable for drug testing and personalized medicine. However, they are more complex to maintain and less amenable to high-throughput genetic manipulation compared to 2D cell lines.

Animal models are critical for studying thyroid cancer in vivo. Examples include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice, preserving the molecular profile of the original tumor.
• • Genetically engineered mouse models (GEMM): Mice with thyroid-specific expression of BRAF V600E or RAS mutations, or with RET/PTC fusions, develop thyroid cancer that recapitulates human disease.
• • Induced models: Use of chemical carcinogens (e.g., N-methyl-N-nitrosourea) or radiation to induce thyroid tumors.
• • Orthotopic models: Injection of human thyroid cancer cells into the mouse thyroid gland to study local invasion and metastasis.

CRISPR-based gene editing has revolutionized the creation of isogenic cell models for thyroid cancer research. These models involve the introduction of specific mutations (knock-in) or gene disruptions (knockout) into a defined genetic background, allowing for precise functional studies. Examples include:

• • TP53 knockout in TPC-1 or BCPAP cells to study the role of p53 loss in dedifferentiation and drug resistance.
• • BRAF V600E knock-in in a BRAF wild-type cell line (e.g., Nthy-ori 3-1) to model the oncogenic effect.
• • RET fusion knock-in (e.g., CCDC6-RET) in a non-transformed thyroid cell line to study transformation.
• • RAS mutant knock-in (e.g., NRAS Q61R) in FTC-133 cells to evaluate MAPK pathway activation.

These gene-edited cell models are commercially available from various sources, with sequence verification and quality control, ensuring reproducibility. They are essential for validating candidate genes, studying drug resistance mechanisms, and screening novel therapeutic agents.

Gene-edited cell models are powerful tools for functional genomics. By creating isogenic pairs (e.g., wild-type vs. knockout), researchers can directly assess the impact of a specific gene on cellular phenotypes such as proliferation, migration, invasion, and apoptosis. Examples:

• • TP53 knockout in thyroid cancer cell lines leads to increased genomic instability and resistance to DNA-damaging agents.
• • BRAF V600E knock-in in normal thyroid cells induces transformation and confers sensitivity to MEK inhibitors.
• • RET knockout in MTC cell lines (e.g., TT) reduces cell growth and induces apoptosis, validating RET as a therapeutic target.

Isogenic cell line pairs are ideal for drug screening and resistance studies. They allow for the identification of genotype-specific drug responses and the elucidation of resistance mechanisms. For example:

• • Screening a panel of BRAF V600E knock-in cells against BRAF inhibitors (e.g., vemurafenib) reveals on-target effects and potential resistance mutations.
• • Creating a TP53 knockout line and treating with doxorubicin or paclitaxel can identify p53-dependent drug sensitivity.
• • Long-term exposure of gene-edited cells to a drug can select for resistant clones, which can then be analyzed by whole-genome sequencing to identify resistance mechanisms (e.g., secondary mutations in NRAS or MAP2K1).

CRISPR-based synthetic lethality screens using gene-edited cell models can identify novel biomarkers and therapeutic targets. For example:

• • In a TP53-null background, knocking out individual genes can reveal vulnerabilities that are specific to p53-deficient cells, such as G2/M checkpoint kinases (e.g., WEE1).
• • In BRAF V600E cells, a CRISPR screen can identify genes whose loss sensitizes cells to MEK inhibitors, providing potential combination targets.
• • Gene-edited reporter lines (e.g., with a fluorescent tag under the control of a thyroid-specific promoter) can be used to screen for compounds that induce differentiation, as a strategy to overcome radioiodine resistance.

The following public databases provide valuable data for thyroid cancer research: